A mechanism for controlled breakage of under-replicated chromosomes during mitosis by Duda, Heike et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
A mechanism for controlled breakage of under-replicated chromosomes
during mitosis
Duda, Heike ; Arter, Meret ; Gloggnitzer, Jiradet ; Teloni, Federico ; Wild, Philipp ; Blanco, Miguel G ;
Altmeyer, Matthias ; Matos, Joao
Abstract: While DNA replication and mitosis occur in a sequential manner, precisely how cells maintain
their temporal separation and order remains elusive. Here, we unveil a double-negative feedback loop be-
tween replication intermediates and an M-phase-specific structure-selective endonuclease, MUS81-SLX4,
which renders DNA replication and mitosis mutually exclusive. MUS81 nuclease is constitutively active
throughout the cell cycle but requires association with SLX4 for efficient substrate targeting. To pre-
clude toxic processing of replicating chromosomes, WEE1 kinase restrains CDK1 and PLK1-mediated
MUS81-SLX4 assembly during S phase. Accordingly, WEE1 inhibition triggers widespread nucleolytic
breakage of replication intermediates, halting DNA replication and leading to chromosome pulverization.
Unexpectedly, premature entry into mitosis—licensed by unrestrained CDK1 activity during S phase—
requires MUS81-SLX4, which inhibits DNA replication. This suggests that ongoing replication assists
WEE1 in delaying entry into M phase and, indirectly, in preventing MUS81-SLX4 assembly. Conversely,
MUS81-SLX4 activation during mitosis promotes targeted resolution of persistent replication intermedi-
ates, which safeguards chromosome segregation.
DOI: https://doi.org/10.1016/j.devcel.2016.11.017
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-131384
Journal Article
Accepted Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Duda, Heike; Arter, Meret; Gloggnitzer, Jiradet; Teloni, Federico; Wild, Philipp; Blanco, Miguel G;
Altmeyer, Matthias; Matos, Joao (2016). A mechanism for controlled breakage of under-replicated
chromosomes during mitosis. Developmental Cell, 39(6):740-755.
DOI: https://doi.org/10.1016/j.devcel.2016.11.017
 1 
A mechanism for controlled breakage of under-replicated 
chromosomes during mitosis 
 
 
 
Heike Duda1, Meret Arter1,4, Jiradet Gloggnitzer1,4, Federico Teloni2,4, Philipp Wild1, 
Miguel G. Blanco3, Matthias Altmeyer2 and Joao Matos1,5 
 
 
 
  
1Institute of Biochemistry, HPM - ETH Zürich, Otto-Stern-Weg 3, 8093 Zürich, 
Switzerland. 
2Department of Molecular Mechanisms of Disease, University of Zurich, 
Winterthurerstrasse 190, 8057 Zürich, Switzerland. 
3Departamento de Bioquímica e Bioloxía Molecular, CIMUS, Universidade de 
Santiago de Compostela, Avda. de Barcelona, 15706 Santiago de Compostela, Spain. 
 
 
4These authors contributed equally to this work 
5Corresponding author: tel +(41) 44 63 36115 
e-mail: joao.matos@bc.biol.ethz.ch 
 
Key words: Cell-cycle, WEE1, CDK1, PLK1, DNA replication, MUS81, SLX4, 
chromosome pulverization 
 
Running title: MUS81-EME2-SLX4 pulverizes under-replicated chromosomes during 
mitosis   
Manuscript
 2 
SUMMARY 
While DNA replication and mitosis occur in a sequential manner, precisely how cells 
maintain their temporal separation and order remains elusive. Here, we unveil a 
double-negative feedback loop between replication intermediates and an M-phase-
specific structure-selective endonuclease, MUS81-SLX4, which renders DNA 
replication and mitosis mutually exclusive. MUS81 nuclease is constitutively active 
throughout the cell cycle, but requires association with SLX4 for efficient substrate 
targeting. To preclude toxic processing of replicating chromosomes, WEE1 kinase 
restrains CDK1 and PLK1-mediated MUS81-SLX4 assembly during S-phase. 
Accordingly, WEE1 inhibition triggers widespread nucleolytic breakage of replication 
intermediates, halting DNA replication and leading to chromosome pulverization. 
Unexpectedly, premature entry into mitosis -licensed by unrestrained CDK1 activity 
during S-phase- requires MUS81-SLX4, which inhibits DNA replication. This 
suggests that ongoing replication assists WEE1 in delaying entry into M-phase and, 
indirectly, in preventing MUS81-SLX4 assembly. Conversely, MUS81-SLX4 
activation during mitosis promotes targeted resolution of persistent replication 
intermediates, which safeguards chromosome segregation. 
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INTRODUCTION 
 
Stable propagation of the genome entails replication of genetic material and 
segregation of duplicated sets of chromosomes prior to cell division. In eukaryotic 
cells these events are separated in time, with gap phases often inserted between the 
two (S-phase and M-phase). It was long assumed that replication intermediates act as 
negative regulators of mitotic entry in order to prevent the catastrophic segregation of 
partly replicated DNAs (Enoch and Nurse, 1991; Hartwell and Weinert, 1989). 
Recent work has challenged this view and it is increasingly well established that even 
unperturbed cells sometimes enter mitosis with under-replicated chromosomes, 
especially if replication stalls late during S-phase (Mankouri et al., 2013). How cells 
adjust M-phase initiation to the completion of DNA replication and how replication 
intermediates are resolved when mitotic entry precedes the conclusion of DNA 
synthesis remains poorly understood. 
Timely and orderly rounds of DNA replication and segregation require oscillatory 
phosphorylation events carried out by cyclin-dependent kinases (CDKs). While S- 
and M-phase cyclin-CDK complexes display a varying degree of functional overlap, 
it is crucial for cells to suppress M-phase CDK levels during DNA replication. In 
agreement, Xenopus egg extracts supplemented with high amounts of cyclin B initiate 
DNA synthesis, but soon after halt S-phase and enter mitosis prematurely (Moore et 
al., 2003). Likewise, in fission yeast and human cells in culture, a surge in CDK 
activity leads to mitotic entry despite the presence of incompletely replicated 
chromosomes (Coudreuse and Nurse, 2010; Heald et al., 1993; Jin et al., 1998). 
Alongside numerous other studies, these observations show that manipulation of the 
overall CDK activity levels is sufficient to change the order of cell cycle events. 
To establish the appropriate length of S-phase, cells adjust the levels of CDK activity 
through inhibitory phosphorylation. The conserved WEE1 and MYT1 kinases 
mediate this phosphorylation event, whereas phosphatases of the CDC25 family 
promote the reverse reaction (Pines, 1999). This mode of CDK regulation is vital for 
genome integrity, especially when problems arise during DNA replication. The ATR 
kinase responds to stalled DNA replication by activating CHK1, a checkpoint kinase 
that interfaces with CDC25 and WEE1, to inhibit CDK1 and delay the onset of 
mitosis (Jackson and Bartek, 2009; Zhou and Elledge, 2000). Interestingly, besides 
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licensing premature entry into mitosis, down-regulation of WEE1 or CHK1 causes 
CDK-dependent breakage of replicating chromosomes (Beck et al., 2010; Beck et al., 
2012; Dominguez-Kelly et al., 2011; Forment et al., 2011). In turn, CDC25A over-
expression leads to replication fork (RF) reversal, which is also followed by CDK1-
dependent DNA cleavage (Neelsen et al., 2013). 
The mechanism by which WEE1/CDC25/CHK1 misregulation causes chromosome 
breakage is not fully understood. Yet, several studies established that it involves 
MUS81, a structure-selective endonuclease with important roles in the metabolism of 
replication intermediates (Beck et al., 2012; Dominguez-Kelly et al., 2011; Forment et 
al., 2011; Kim et al., 2013; Neelsen et al., 2013; Techer et al., 2016). In mammals, 
MUS81 forms heterodimeric complexes with the non-catalytic subunits EME1 or 
EME2 (Pepe and West, 2014a). Both MUS81-EME1 and MUS81-EME2 are capable 
of cleaving Y-shaped duplex DNAs in vitro, suggesting that RFs may be 
physiological MUS81 substrates in vivo (Pepe and West, 2014b). In agreement with 
this notion, MUS81 has been implicated in the nucleolytic processing of stalled RFs 
after prolonged S-phase arrest (Hanada et al., 2007). Moreover, by cleaving persistent 
replication intermediates during M-phase, MUS81 promotes DNA repair synthesis 
outside S-phase and safeguards faithful chromosome segregation (Minocherhomji et 
al., 2015; Naim et al., 2013; Ying et al., 2013). 
It remains elusive, though, how cells achieve efficient processing of stalled RFs after 
prolonged arrest or in M-phase, while avoiding the toxic cleavage of related DNA 
structures during unperturbed S-phase. Since WEE1 kinase prevents MUS81-
dependent DNA breakage, it has been suggested that WEE1 may directly 
phosphorylate and inhibit MUS81, specifically during S-phase (Dominguez-Kelly et 
al., 2011). On the other hand, MUS81-mediated processing of Holliday junctions 
(HJs), generated during recombinational DNA repair, is upregulated at the onset of 
mitosis (Gallo-Fernandez et al., 2012; Matos et al., 2011; Matos et al., 2013; Szakal 
and Branzei, 2013; Wyatt et al., 2013). CDK1-dependent interaction with the scaffold 
protein SLX4 coordinates the nickase activity of another structure-selective nuclease, 
SLX1, with subsequent HJ incision by MUS81 (Castor et al., 2013; Fekairi et al., 
2009; Gritenaite et al., 2014; Matos et al., 2011; Munoz et al., 2009; Svendsen et al., 
2009; Wyatt et al., 2013). Hence, regulated activation of MUS81 at the G2/M 
transition could provide an alternative explanation for its limited ability to cleave RFs 
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during S-phase, while efficiently processing stalled replication intermediates at the 
onset of mitosis. 
Here, we have investigated how cells dynamically adjust MUS81 nuclease activity 
towards replication intermediates during the cell cycle. Unexpectedly, by outlining 
the mechanism of MUS81 control, we reveal its pivotal role within a regulatory 
network that ensures that DNA replication and mitosis occur sequentially and in a 
mutually exclusive manner. MUS81 regulation avoids detrimental cleavage of 
replication intermediates, which can lead to chromosome pulverization. 
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RESULTS 
MUS81 nuclease is constitutively active throughout the cell cycle 
To investigate if MUS81 activity towards replication intermediates is regulated during 
the cell cycle we immunopurified MUS81-FLAP, expressed at endogenous levels, 
from cells collected at 2-hr intervals after release from a double-thymidine block. We 
then incubated the immunoprecipitated (IP) material with a synthetic Y-shaped 
dsDNA structure that resembles branched DNA at the RF, and is a bona fide substrate 
of recombinant MUS81 (Pepe and West, 2014b). Incubation of this model RF with 
MUS81-FLAP IPs resulted in robust cleavage of the substrate (Figure 1A-C). 
Notably, however, MUS81 activity remained unchanged throughout the time course 
(Figure 1A-C). To confirm this result, we compared the activity of MUS81 from cells 
synchronized at G1/S with cells synchronized in prometaphase. MUS81 IPs from both 
cell cycle stages showed similar kinetics in RF processing (Figure S1A-C). 
Since cleavage of Holliday junctions (HJs) by MUS81 is cell cycle regulated and 
increases upon SLX1-SLX4 binding at the G2/M transition (Figure S1D, left panel) 
(Castor et al., 2013; Matos et al., 2011; Wyatt et al., 2013), we tested whether SLX1 
also stimulates MUS81 activity on model RF substrates. In contrast to HJ processing, 
depletion of SLX1 did not noticeably reduce the ability of MUS81 IPs to process 
model RFs (Figure 1D and Figure S1E). This does not exclude the possibility that the 
function of a fraction of MUS81 nuclease may be modulated by protein-protein 
interactions and/or post-translation modifications. However, these data suggest that 
the catalytic activity of MUS81 is neither inhibited prior to mitosis, nor globally 
stimulated through interaction with SLX1-SLX4 nuclease. 
 
SLX4 controls the association of multiple MUS81 molecules and their 
recruitment to under-replicated regions during mitosis 
MUS81 is known to associate with chromatin at under-replicated regions during 
mitosis (Naim et al., 2013; Ying et al., 2013). Since MUS81-SLX4 association 
occurred with similar timing, we examined if SLX4 also binds chromatin in mitosis 
and whether it plays a role in MUS81 recruitment. To follow SLX4 localization, we 
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used immunofluorescence microscopy in cell lines stably expressing SLX4-FLAP. In 
cells with condensed chromatin, indicative of mitotic entry, SLX4-FLAP was 
frequently enriched in discrete foci, whose number varied between cells (Figure 1F). 
The majority of mitotic SLX4-FLAP co-localized with MUS81 and with known 
components of stalled replisomes (Figure 1E, data not shown)(Gritenaite et al., 2014; 
Naim et al., 2013; Pedersen et al., 2015; Ying et al., 2013). 
We next asked whether SLX4 is required for targeting MUS81 to stalled replication 
intermediates. In agreement with recent reports (Guervilly et al., 2015; 
Minocherhomji et al., 2015), we found that SLX4 depletion strongly impaired 
MUS81 recruitment to subnuclear foci during mitosis (Figure 1G and H). 
Accordingly, SLX4 depletion caused a 10-fold decrease in MUS81 recruitment to 
TOPBP1 foci (Figure 1I). 
Besides targeting MUS81 to stalled replication intermediates during mitosis, we 
noticed that SLX4 regulates MUS81 through an additional mechanism. Analysis of 
MUS81-FLAP IPs showed that endogenous MUS81 was enriched in nocodazole- but 
not in thymidine-treated cells (Figure S1A, Figure S2A, data not shown). Since 
MUS81-SLX4 interaction occurred with a similar timing (Figure S2A), we asked 
whether association of multiple MUS81 molecules might be SLX4-dependent. 
Indeed, upon depletion of SLX4, endogenous MUS81 was no longer detected in 
MUS81-FLAP IPs (Figure S2B). Therefore, SLX4 promotes association of multiple 
MUS81 molecules, specifically at the onset of mitosis. 
 
Phosphorylation of SLX4 is required for MUS81 binding during mitosis 
In previous work, we showed that MUS81-SLX4 association requires CDK1 activity, 
but its direct substrate(s) in this process remain elusive (Wyatt et al., 2013). Since 
SLX4 is phosphorylated at 30 of 41 minimal CDK consensus sites (S/TP) (Figure 
2A), we sought to generate an SLX4 mutant fully refractory to CDK- 
phosphorylation. To this end we engineered SLX441A, which encodes alanine 
substitutions of all serines or threonines preceding a proline. Expression of FLAG-
tagged SLX441A in HeLa cells revealed that the alanine substitutions did not impair 
SLX4 stability, compared to SLX4WT (Figure 2B). In addition, SLX441A IPs showed 
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normal association with both SLX1 and XPF, indicating that the folding of the mutant 
protein was largely preserved. Notably, however, SLX441A IPs lacked MUS81 (Figure 
2B), suggesting that phosphorylation may promote a domain-specific change in SLX4 
required for MUS81 binding. Since MUS81 interacts with the SAP domain of SLX4 
(Figure 2A)(Castor et al., 2013; Kim et al., 2013), we mutated the 6 S/TP sites on the 
C-terminus of SLX4, and generated SLX46A. In addition, we generated the 
complementary mutant by targeting the remaining 35 sites (SLX435A). Remarkably, 
while SLX435A showed normal binding to MUS81, mutation of the 6 S/TP sites 
surrounding the SAP domain abolished SLX4-MUS81 complex formation (Figure 
2C). These data argue that CDK1-mediated phosphorylation of the SAP domain in 
SLX4 is part of the M-phase-specific switch that controls MUS81 association. 
 
WEE1 inhibits CDK1 to prevent MUS81-SLX4 association during S-phase 
Our results led us to suspect that, rather than inhibiting MUS81 activity directly, as 
previously suggested (Dominguez-Kelly et al., 2011), WEE1 suppresses toxic 
processing of replication intermediates by preventing MUS81-SLX4 association 
during S-phase. To test this hypothesis we synchronized cells at G1/S, and released 
cultures in the presence of the small molecule inhibitor MK-1775 (hereinafter referred 
to as WEE1i), which has been extensively validated for selective inhibition of WEE1 
in vitro and in vivo (Aarts et al., 2012; Beck et al., 2012; Hirai et al., 2009). We then 
immunoprecipitated SLX4 from samples collected at 2-hr intervals and analyzed the 
immunoprecipitated material for the presence of MUS81. Whereas control cells 
showed MUS81-SLX4 association 6 hrs after release from thymidine, cells treated 
with WEE1i showed similar levels of MUS81-SLX4 interaction already 2 hrs after 
release (Figure 2D). 
Since the SLX4-MUS81 complex forms at the G2/M transition, we examined if 
changes in SLX4-associated RF-processing activities were detected throughout the 
cell cycle. Indeed, SLX4-FLAP IPs showed a strong increase in RF cleavage shortly 
before mitotic entry, which correlated with MUS81 association (Figure 2D and E, left 
panels). Importantly, siRNA-mediated depletion of MUS81 reduced the 
prometaphase-specific increase in RF-processing activity of SLX4 IPs (Figure S2C). 
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Moreover, inhibition of WEE1 advanced the peak of SLX4-associated RF processing 
in time, further strengthening a model in which WEE1 prevents SLX4 complexes 
from acquiring the ability to process replication intermediates prematurely (Figure 2D 
and E). In contrast, the RF-processing activity of MUS81 IPs remained constant, 
confirming that WEE1 does not directly inhibit the nuclease activity of MUS81 
(Figure S2D). Under identical experimental conditions, MUS81-mediated HJ 
processing increased upon SLX4-SLX1 association and, accordingly, was advanced 
in time as a consequence of WEE1 inhibition (Figure S1D). 
Since WEE1 phosphorylates CDK1 to reduce its activity during S-phase (Russell and 
Nurse, 1987), we reasoned that WEE1 could indirectly restrain MUS81-SLX4 
interaction. To test this scenario we inhibited CDK1 (RO-3306) or PLK1 (BI2536) in 
cells treated with WEE1i and analyzed MUS81-SLX4 complex formation. Inhibition 
of CDK1 reduced MUS81-SLX4 association during S-phase and strongly reduced the 
ability of SLX4 IPs to process model RFs (Figure 2D and E). Upon PLK1 inhibition, 
we observed a delay of ~6 hrs in MUS81-SLX4 association, which was mirrored by 
late activation of SLX4 to process model RFs (Figure 2D and E). WEE1 inhibition 
also induced a CDK1-dependent electrophoretic mobility shift in SLX4, during S-
phase (2-6 hr after thymidine release) (Figure 2D). This is consistent with a model in 
which CDK1-mediated phosphorylation of SLX4 directly controls MUS81 
association (Wyatt et al., 2013)(Figure 2D). 
 
WEE1 activity prevents recruitment of MUS81-SLX4 nuclease to replicating 
chromosomes during S-phase 
We next examined if binding to SLX4 elicited recruitment of MUS81 to replicating 
chromosomes. We released pre-synchronized cells to undergo S-phase in the presence 
or absence of WEE1 inhibitor, and imaged MUS81 and SLX4 at different time points 
after release (3 hrs and 9 hrs, to enrich for S-phase and mitosis, respectively). 98% of 
all S-phase cells treated with WEE1i showed widespread MUS81 and SLX4-FLAP 
chromatin association and extensive colocalization (Figure 2F). The majority of 
control cells (93%) exhibited predominantly nucleolar MUS81, which co-localized 
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poorly with SLX4 (Figure 2F). Both control and WEE1i-treated cells showed similar 
levels of the S-phase marker PCNA (Figure 2G).  
In cells treated with WEE1i, just 3 hrs after release from G1/S, a small fraction of the 
population (~3%) displayed early mitosis features, such as condensed chromatin and 
bright MUS81 foci that co-localized with SLX4, TOPBP1 and -H2AX (Figure S2E, 
data not shown). In these cells, the number of MUS81 foci was 2-3 fold higher than in 
control cells with similarly condensed DNA (collected 9 hrs after G1/S release) 
(Figure S2E and F). This suggests that in cells that are close to completing DNA 
replication, inhibition of WEE1 licenses recruitment of MUS81-SLX4 to a moderate 
number of under-replicated chromosomal regions. 
 
MUS81-SLX4 association during S-phase leads to chromosome pulverization 
and halts DNA replication 
Since WEE1 inhibition at the onset of S-phase caused recruitment of active MUS81 to 
chromosomes, we anticipated it would be highly deleterious to DNA replication. To 
test this prediction, also supported by previous work (Beck et al., 2010; Beck et al., 
2012; Dominguez-Kelly et al., 2011), we released synchronized cells to undergo S-
phase in the presence of WEE1i and used flow cytometry to monitor DNA content at 
2-hr intervals. Cells treated with WEE1i initiated DNA replication with similar 
kinetics to DMSO-treated cells. However, whereas control cells completed DNA 
replication 6-8 hrs after release from G1/S, cells lacking WEE1 activity appeared to 
arrest bulk DNA synthesis shortly after initiation, displaying a persistent ~3C DNA 
content (Figure 3A and B). 
If WEE1 inhibition leads to impaired DNA replication through toxic cleavage of RFs, 
we would expect a direct link between premature MUS81-SLX4 association and 
DNA breakage. Indeed, western-blot analysis of -H2AX and KAP1 phosphorylation 
indicated prompt activation of the DNA-damage response just 2 hrs after cells were 
released to undergo S-phase in the presence of WEE1i (Figure 3C). Parallel analysis 
of MUS81-FLAP IPs confirmed that the occurrence of DNA damage correlated 
tightly with the timing of MUS81-SLX4 complex formation and the inhibition of 
DNA replication (Figure 3A and D). Interestingly, binding of EME1 and EME2 to 
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MUS81 did not significantly change throughout the cell cycle or in response to WEE1 
inhibition (Figure 3D, Figure S1D). Hence, both non-catalytic subunits might 
contribute to the WEE1i-triggered DNA damage. 
Our results led us to hypothesize that the uncontrolled actions of MUS81-SLX4 on 
replication intermediates should result in widespread chromosomal breakage. 
Therefore, we monitored the consequences of WEE1 inhibition on the morphology of 
metaphase chromosomes in surface spreads. Whereas control cells showed intact 
chromosomes with sporadic DNA lesions, 94% of cells treated with WEE1i exhibited 
chromosomes with a pulverized appearance (Figure 3E and F). The remaining 
fraction of WEE1i-treated cells (6%) displayed non-pulverized chromosomes that 
nevertheless contained a 30-fold increase in DNA lesions (breaks and radial 
chromosomes) compared to untreated cells (Figure 3E and F). The two populations of 
metaphase spreads (pulverized vs. damaged) are likely to reflect MUS81-SLX4 
recruitment to early or late S-phase chromosomes (widespread vs. increased foci, 
respectively) (Figure 2F, S2E and F). Chromosome pulverization triggered by WEE1i 
was also observed in asynchronous HeLa cultures. Here, the fraction of pulverized 
metaphases was lower and increased with time, likely reflecting the asynchronous 
passage through S-phase (Figure S3A). 
The unusually high levels of DNA breakage caused by WEE1 inhibition could be 
confirmed by in situ immunofluorescence analysis of -H2AX, which displayed a 
pan-nuclear distribution in cells released to undergo S-phase in the presence of 
WEE1i (Figure S2G). Furthermore, analysis of chromosome integrity using pulsed-
field gel electrophoresis (PFGE) revealed that more than 65% of all chromosomal 
DNA was fragmented after just 5 hrs of WEE1 inhibition (Figure 3G). 
 
DNA fragmentation upon WEE1 inhibition is not caused by RPA exhaustion or 
induction of apoptosis 
The excessive accumulation of RPA at stalled replication forks has been shown to 
precede widespread DNA damage, in a process controlled by the checkpoint kinase 
ATR (Toledo et al., 2013). Since WEE1 has been suggested to prevent excessive 
origin firing during S-phase (Beck et al., 2012), we sought to determine whether 
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exhaustion of RPA precedes DNA breakage in cells treated with WEE1i. Analysis of 
-H2AX and RPA levels by quantitative image-based cytometry (QIBC) (Toledo et 
al., 2013) showed that WEE1i treatment induced MUS81-EME2-dependent 
accumulation of DNA damage, without significantly affecting the levels of 
chromatin-bound RPA (Figure 3H and I, Figure S3B and C). In contrast, control cells 
treated with HU and ATRi displayed elevated levels of -H2AX with concomitant 
exhaustion of cellular RPA, as previously shown (Figure 3H and I, Figure 
S3B)(Toledo et al., 2013). 
Since chromosome fragmentation is also known to occur during programmed cell 
death (Nagata et al., 2003), we examined if cells treated with WEE1i showed signs of 
apoptosis. Western-blot analysis of Caspase 3 and PARP integrity showed no 
evidence for their proteolytic cleavage within the timeline of chromosomes 
pulverization (Figure S3D, data not shown). 
 
WEE1 suppresses CDK1 and PLK1-dependent MUS81-SLX4 complex 
formation to prevent pulverization of S-phase chromosomes 
Since CDK1 and PLK1 activities were required for timely MUS81-SLX4 association 
(Figure 2D), we predicted that inactivation of either kinase should restore DNA 
replication after WEE1 inhibition. Indeed, FACS analysis revealed that CDK1 and 
PLK1 inhibitors fully restored the bulk of DNA synthesis in cells released to undergo 
S-phase in the presence of WEE1i (Figure 4A, data not shown). Furthermore, over 
70% of cells co-treated with WEE1i and CDK1 or PLK1 inhibitors displayed intact 
chromosomes (Figure 4B and C). 
In contrast to previous models postulating that WEE1 inhibition causes DNA damage 
due to excessive activity of the S-phase kinase CDK2 (Beck et al., 2012; Dominguez-
Kelly et al., 2011), these data rather suggest that the vast majority of DNA breakage is 
triggered by premature activation of the mitotic kinases CDK1 and PLK1. 
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EME2 collaborates with MUS81-SLX4 in processing replication intermediates 
upon WEE1 inhibition 
To verify if chromosome pulverization caused by WEE1 inhibition depends on 
MUS81-SLX4 nuclease, we monitored DNA damage in cells transfected with siRNAs 
targeting MUS81, SLX1 or SLX4. Indeed, chromosome spreads, PFGE and western 
blot analysis of KAP1 phosphorylation revealed a marked reduction in DNA breakage 
upon MUS81 or SLX4 depletion (Figure 4D and E, S4A). Simultaneous depletion of 
SLX4 and MUS81 did not show additive effects, suggesting that both are components 
of the same RF-processing pathway (Figure 4D, data not shown). By contrast, SLX1 
depletion did not significantly alter DNA breakage after WEE1 inactivation (Figure 
4D and S4A). Importantly, expression of siRNA-resistant catalytically inactive 
MUS81 (D307A) did not restore DNA damage and chromosome fragmentation in 
cells depleted of endogenous MUS81 (Figure S4B-D). This establishes that MUS81 
nuclease is directly involved in generating DNA lesions upon inhibition of WEE1. 
Next, we investigated if EME1 and EME2 contribute to the toxic processing of 
replication intermediates. siRNAs targeting EME2 almost entirely suppressed 
chromosome breakage in HeLa cells (Figure 4D, E and S4A) and DNA damage 
signaling in RPE1-hTERT cultures (Figure S4E). We were unable to determine the 
relative importance of EME1 using this approach since the tested siRNAs caused 
elevated levels of cell death upon synchronization (data not shown). To circumvent 
this problem, we obtained HAP1 cell lines carrying frame-shift mutations in EME1, 
EME2 or MUS81 (Figure S4F, see Note 1 in Extended Experimental Procedures 
describing evidence for the existence of two isoforms of MUS81: MUS81 and 
MUS81short). We then treated subconfluent cultures of each cell line with WEE1i, and 
measured DNA damage by PFGE and western-blot analysis of -H2AX and KAP1 
phosphorylation. Cells lacking EME1 showed reduced levels of DNA damage 
induction (Figure 4F and S4G), indicating that EME1 contributes to the efficient 
cleavage of replication intermediates upon WEE1 inhibition. However, cells lacking 
EME1 showed a substantial reduction in MUS81 levels, unlike cells lacking EME2 
(Figure 4F). Hence, EME1 may promote DNA damage indirectly, through 
stabilization of the cellular pool of MUS81 protein. 
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These data suggest that MUS81, EME2 and SLX4, but not SLX1 or MUS81short, are 
components of a protein complex whose premature assembly promotes deleterious 
breakage of replicating chromosomes. 
 
Inactivation of MUS81 improves cell survival after WEE1 inhibition 
Since WEE1 inhibition caused extensive DNA damage, we asked whether cells with 
pulverized chromosomes would be capable of undergoing cell division. To test this, 
we used time-lapse microscopy in cells expressing histone H2B-mCherry (Schmitz et 
al., 2010). Cells treated with WEE1i failed to align chromosomes in a metaphase 
plate, showed signs of chromosome fragmentation, failed to undergo efficient 
chromosome segregation and after a prolonged M-phase eventually exited mitosis 
without dividing (Figure 5A and B, Movie S1). Depletion of EME2 or SLX4 
significantly restored chromosome morphology, along with chromosome segregation 
and cell division (Figure 5A and B, Movie S1, data not shown).  
WEE1i (MK-1775) has been shown to selectively sensitize cancer cells to DNA-
damaging agents and is in phase II trials for treatment of a broad range of tumors 
(Aarts et al., 2012; Hirai et al., 2009). Since MUS81-EME2-SLX4 contributes to 
several phenotypes associated with loss of WEE1 function, we determined whether 
cellular mortality caused by WEE1i was MUS81-EME2-SLX4-dependent. To 
monitor short-term cell death in HAP1 cells we used time-lapse microscopy to follow 
their morphology. After 22 hrs of treatment with WEE1i, ~85% of parental HAP1 
cells displayed apoptotic bodies, membrane blebbing and loss of motility. In contrast, 
cells lacking MUS81 or EME2 showed a significantly higher survival rate (Figure 5C, 
data not shown). To confirm these data, we followed long-term cell survival using a 
clonogenic assay. In agreement with the short-term data, WEE1i reduced colony 
formation in a MUS81 and EME2-depedent manner (Figure 5D). 
We next examined cell viability in Fanconi Anemia patient cell lines (FA-P) lacking 
SLX4 expression (Kim et al., 2013). Similar to HAP1 or HeLa cells, FA-P cells 
complemented with a vector carrying SLX4-WT were significantly more sensitive to 
increasing concentrations of WEE1i than cells transduced with an empty vector 
(Figure 5E). Crucially, complementation with a truncated SLX4 version that lacks the 
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SAP domain (Kim et al., 2013), did not restore sensitivity to WEE1i (Figure 5E). This 
indicates that SLX4 interaction with MUS81 is important for its role in triggering cell 
death in response to WEE1 inhibition. 
We conclude that MUS81-EME2-SLX4 contributes to cell death after WEE1 
inhibition, suggesting that an intact MUS81-EME2-SLX4 pathway may be an 
important requirement for successful usage of WEE1 inhibitors in the clinic. 
 
Inhibition of DNA replication by MUS81-EME2-SLX4 licenses premature entry 
into mitosis 
The replication arrest caused by WEE1 inactivation raised the intriguing possibility 
that widespread cleavage of replication intermediates may drive premature entry into 
mitosis, a hallmark feature of cells with impaired WEE1 function (Heald et al., 1993; 
Russell and Nurse, 1987)(Figure 3B). To test this model we first examined whether 
inhibition of PLK1 or depletion of MUS81-EME2-SLX4 restored DNA replication in 
cells treated with WEE1i. Indeed, as discussed above, FACS analysis of DNA content 
revealed that PLK1 inhibitors reestablished normal S-phase progression (Figure 4A). 
Albeit with a slight delay, depletion of MUS81, SLX4 or EME2 also reproducibly 
restored DNA replication (Figure S5A). The level of rescue was proportional to the 
reduction in chromosome breakage observed by PFGE (Figure 4D), with EME2 
depletion efficiently restoring the bulk of DNA synthesis. 
Having created conditions in which DNA replication takes place in the presence of 
unrestrained CDK1 activity, we next examined whether a temporal intersection 
between DNA replication and mitosis would occur. Remarkably, inhibition of PLK1 
or depletion of MUS81-EME2-SLX4 delayed the onset of mitosis in cells treated with 
WEE1i (Figure 6A-E, Figure S5B, Movie S2). For EME2 depletion or PLK1 
inhibition a near-complete rescue of mitotic entry timing was observed. To further 
investigate this model, we treated asynchronous HeLa cultures with WEE1i and 
monitored cell cycle stage distribution using QIBC. Consistent with the results from 
synchronized cells, a 3-hr treatment with WEE1i led to an EME2-dependent 
accumulation of nuclear Cyclin B in cells with an S-phase DNA content (Figure 6F-H 
and S6A, C and D). In turn, the premature accumulation of Cyclin B correlated with 
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pan-nuclear DNA damage, which was equally reduced by depletion of EME2 (Figure 
6F-I, S6A-D). 
To test our findings in a non-transformed cell line, we studied the consequences of 
WEE1 inhibition in RPE1-hTERT cells. As in HeLa cells, WEE1 inhibition caused 
EME2-dependent DNA damage, replication arrest, premature accumulation of Cyclin 
B and premature cell rounding in cells released from a single thymidine block (Figure 
S7A). This could also be confirmed in asynchronous populations using QIBC: 
treatment with WEE1i caused EME2-dependent DNA damage (Figure S7B) and mild 
but reproducible accumulation of Cyclin B in cells with a mid and late S-phase DNA 
content (Figure S7C-F, data not shown). 
Overall, these data suggest that suppression of CDK1 activity during S-phase prevents 
MUS81-EME2-SLX4-mediated premature entry into M-phase. 
 
WEE1 suppresses EME2-dependent activation of CDK1 during S-phase 
We next asked whether MUS81-EME2-SLX4 was required for premature CDK1 
activation upon inhibition of WEE1. To this end, we monitored the impact of EME2 
depletion on the phosphorylation of CDC27, a well-characterized substrate of CDK1 
(Peters et al., 1996). Inhibition of WEE1 impaired DNA replication in control cells 
and led to premature modification of CDC27, which coincided with the detection of 
DNA damage (KAP1-P) (Figure 7A and B). Notably, depletion of EME2 was 
sufficient to delay phosphorylation of CDC27 until the bulk of DNA synthesis was 
completed, approximately 6 hrs after release from G1/S (Figure 7A and B). 
Nevertheless, phosphorylation of CDC27 still occurred prematurely in cells lacking 
EME2, presumably due to unrestrained activation of CDK1 in cells that completed 
DNA replication and transitioned into G2 (Figure 7B). 
 
ATR-independent inhibition of mitotic entry by ongoing DNA replication 
Previous work established that the checkpoint kinase ATR prevents premature mitosis 
during unperturbed growth to ensure sufficient DNA replication (Eykelenboom et al., 
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2013). Hence, we suspected the delay in CDK1 activation caused by depletion of 
EME2, in cells treated with WEE1i, might be ATR-mediated. However, three lines of 
evidence argued against this model. First, western-blot analysis of CHK1 (S345) and 
RPA (S33) phosphorylation revealed that WEE1 inhibition alone caused robust 
activation of ATR, despite triggering premature entry into mitosis (Figure 7B). 
Second, depletion of EME2, which restored DNA replication, robustly reduced CHK1 
and RPA phosphorylation while DNA replication was ongoing (Figure 7A and B). 
Third, chemical inhibition of ATR -or ATR and ATM combined- did not drastically 
advance the onset of mitosis in cells treated with WEE1i and depleted of EME2 
(Figure 7C and D). Hence, while our data suggest that ATR is active in the absence of 
WEE1 activity, ATR activity does not appear to suffice in preventing entry into 
mitosis if replication intermediates are cleaved by MUS81 nuclease.  
 
DISCUSSION 
 
A mechanism for targeted breakage of replication intermediates during mitosis 
Previous studies revealed a key role for MUS81 endonuclease in the resolution of 
stalled replication intermediates at the onset of mitosis (Naim et al., 2013; Ying et al., 
2013). However, whether and how cells prevent MUS81 from cleaving vital DNA 
structures during unperturbed S-phase was unclear. The present work establishes that 
MUS81 is biochemically able to process model RFs at all stages of the cell cycle, but 
requires association with SLX4 for efficient substrate targeting in vivo. Since 
MUS81-SLX4 association is controlled by CDK1-mediated phosphorylation of 
SLX4, MUS81 is actively targeted to replication intermediates only after the bulk of 
DNA replication is completed. Therefore, by coupling MUS81-SLX4 association to 
mitotic entry, cells achieve the selective cleavage of replication intermediates that fail 
to activate the DNA replication checkpoint. This dynamic regulation prevents stalled 
replication intermediates from impairing chromosome segregation, while enabling 
functional replication forks to drive DNA replication during S-phase (Figure 8A and 
B). 
 
WEE1 prevents unscheduled processing of vital replication intermediates by 
precluding exposure of S-phase chromosomes to MUS81-SLX4 
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Our work demonstrates that MUS81 plays a significant role in triggering cell death 
upon treatment with the WEE1 inhibitor MK-1775. We find that MUS81 is important 
for the drug to be fully effective in triggering cell death in different cancer cell lines, 
and provide important new insight into its precise mechanism of action. WEE1 
inhibition causes premature activation of the cell cycle kinases CDK1 and PLK1, 
resulting in unscheduled MUS81-SLX4 association. This exposes replicating 
chromosomes to MUS81-SLX4 nuclease, triggering cleavage of vital replication 
intermediates. Therefore, rather than directly inhibiting MUS81 activity as previously 
suggested (Dominguez-Kelly et al., 2011), we propose that WEE1 prevents DNA 
breakage by suppressing CDK1 activity prior to the completion of DNA replication 
(Figure 8B). 
Impaired WEE1 function was reported to cause excessive origin firing and nucleotide 
shortage, followed by MUS81-dependent DNA damage (Beck et al., 2012; 
Dominguez-Kelly et al., 2011). This led to a model in which WEE1 inhibition causes 
remodeling of RFs, converting them into MUS81 substrates (Beck et al., 2012). We 
show that EME2 depletion and PLK1 inhibition efficiently restore the bulk of DNA 
replication in cells treated with WEE1 inhibitors, arguing that a significant fraction of 
replication intermediates targeted for cleavage is capable of supporting DNA 
synthesis effectively. Therefore, even though most naturally-occurring MUS81 
substrates are likely to be stalled RFs (Beck et al., 2012; Naim et al., 2013; Neelsen et 
al., 2013; Ying et al., 2013), we envision that RF remodeling may not be a pre-
requisite for substrate recognition and cleavage. In agreement with this model, WEE1 
inhibition triggers massive DNA breakage and chromosome pulverization without 
significantly altering the recruitment of RPA to replicating chromosomes (Figure 3H 
and I). The data described here does not exclude the possibility that MUS81-mediated 
cleavage of replication intermediates may not be solely responsible for the cessation 
of DNA replication in cells treated with WEE1 inhibitors. It is conceivable, for 
example, that the breakage of a fraction of replication intermediates triggers 
premature entry into M-phase and nuclear envelope disassembly, which could further 
contribute to the inhibition of DNA replication. 
Besides targeting MUS81 to stalled replication intermediates, SLX4 regulates HJ 
processing by coordinating the active sites of MUS81 and SLX1 nucleases (Castor et 
al., 2013; Wyatt et al., 2013). Accordingly, WEE1 activity also prevented premature 
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MUS81-EME1-SLX1-SLX4 complex formation (Figure S1D). Hence, besides 
precluding the toxic processing of replication intermediates, WEE1 is likely to play an 
important role in restricting resolution of recombination intermediates to late stages of 
the cell cycle. In yeast, analogous suppression of Mus81-Mms4 function during S-
phase plays a critical role in preventing the formation of crossover recombinants and 
in suppressing loss of heterozygosity (Matos et al., 2013; Szakal and Branzei, 2013; 
Wild and Matos, 2016). 
 
Making DNA replication and mitosis mutually exclusive and ordered 
To explain how cells order S-phase and mitosis, Stern and Nurse have put forward a 
quantitative model for CDK control (Stern and Nurse, 1996). S-phase is initiated 
when CDK activity increases from a very low to a moderate level, whereas a further 
increase to high CDK activity initiates mitosis. Accordingly, up-regulation of CDK1 
activity during S-phase, by Cyclin B over-expression or WEE1 inactivation, drives 
mitotic entry prior to the completion of DNA replication (Coudreuse and Nurse, 2010; 
Moore et al., 2003; Russell and Nurse, 1987). Our work suggests that CDK1 up-
regulation during S-phase drives premature entry into mitosis partly due to the 
untimely assembly of a nuclease capable of halting DNA replication: MUS81-SLX4. 
When WEE1 is inhibited in cells lacking MUS81-SLX4, DNA replication is 
significantly restored and mitotic entry shows a concurrent delay. Therefore, we 
envision that by keeping CDK1 and MUS81-SLX4 in check, WEE1 prevents 
disappearance of a signal, likely generated by replication intermediates, that inhibits 
M-phase entry. 
In agreement with work in yeast (Magiera et al., 2014), our data raise the interesting 
possibility that RFs, the target of MUS81-SLX4, negatively regulate M-phase entry 
by delaying CDK1 activation (Figure 8B). Once DNA replication is completed, the 
inhibitory signal disappears, allowing CDK1 activity levels to rise. In turn, CDK1 
activity licenses MUS81-SLX4 assembly, which resolves any remaining replication 
intermediates. This double-negative feedback loop warrants that DNA replication and 
mitosis are mutually exclusive. Furthermore, in conjunction with CDK1 regulators 
such as WEE1, it ensures that DNA replication temporally precedes mitosis (Figure 
8B). 
 
A mechanism for chromosome pulverization and chromothripsis? 
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It has been suggested that one underlying reason for the temporal separation of DNA 
replication and mitosis, in eukaryotic cells, is that DNA replication and chromosome 
condensation might be incompatible (Nasmyth, 1995; Stern and Nurse, 1996). It has 
also been proposed that, as a consequence of premature compaction, limited 
chromosome pulverization can occur if a micronucleated cell enters mitosis with an 
under-replicated micronucleus (Crasta et al., 2012). These findings are relevant for 
human health since they provide insights into the phenomenon of chromothripsis (Liu 
et al., 2011; Stephens et al., 2011). 
In light of the present work, we would like to suggest a complementary explanation to 
the incompatibility between DNA replication and mitosis, which takes into account a 
straightforward mechanism to achieve chromosome pulverization: MUS81-SLX4 
cleaves replication intermediates that fail to inhibit mitotic entry. The strength of such 
model in explaining previous observations related to chromosome shattering events 
that precede chromothripsis (Forment et al., 2012) is at least four-fold: 1) it is 
compatible with shattering of a single or multiple chromosomes (e.g. if a single 
chromosome is found in in a micronucleus, only this chromosome will lag in DNA 
replication and become a target of MUS81); 2) the level of chromosome breakage is 
dependent on how under-replicated the particular chromosome is; 3) if more than one 
chromosome is under-replicated, inter-chromosomal translocations can occur; 4) 
CDK1 and PLK1, which act as timers of MUS81-SLX4 assembly, are misregulated in 
a multitude of cancers (Lee et al., 2015; Malumbres and Barbacid, 2009) and 
therefore replicating chromosomes in these cancer cells may be frequently exposed to 
the severing actions of MUS81-SLX4. 
 
 
EXPERIMENTAL PROCEDURES 
All experimental procedures are described in detail in the Supplemental Information. 
Cell assays 
RPE1-hTERT, HAP1, HeLa FRT/TO and HeLa Kyoto cells were maintained in 
DMEM supplemented with 10% FBS. FA-P cells were maintained in DMEM 
supplemented with 20% FBS. For siRNA-mediated protein depletion, cells were 
plated to ~30% confluency, 10-12 hr prior to transfection. The efficiency of protein 
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depletion was monitored by western blotting 44-60 hrs after transfection. HeLa Kyoto 
cells stably expressing MUS81-FLAP (CLJM6) (Matos et al., 2011) or SLX4-FLAP 
(CLJM59) (this study) were generated using BAC recombineering. Cells expressing 
SLX4-FLAP show a G2/M-specific increase in MUS81 levels (data not shown). This 
is caused by stabilization of MUS81 by interaction with the additional SLX4-FLAP 
protein, which is G2/M specific. 
To follow the progression of G1/S arrested cells into mitosis, cells were synchronized 
with a double thymidine block (15-16 hrs) and released into pre-warmed medium. 
Unless otherwise indicated, MK-1775 (WEE1i) was used at a final concentration of 
500 nM. 
 
Short-term and long-term cell survival assays 
HAP1 cells were treated with MK-1775 and followed by time-lapse microscopy. 
Short-term cell survival was calculated by determining the fraction of living cells to 
the total number of cells in the first and last frame of the movie and expressed as %. 
Long-term survival of HAP1 cells was determined using a clonogenic assay. Cells 
were treated for 6 hrs with MK-1775 at final concentrations from 50 nM to 500 nM. 
After one week, cells were fixed and stained with crystal violet solution. FA-P cells 
were treated for 6 hrs with MK-1775 at concentrations ranging from 400 to 1200 nM. 
Cell survival was determined five days later using the Cell Titer-Glo 2.0 reagent 
(Promega). 
 
Quantitative Image-Based Cytometry  
Automated multichannel wide-field microscopy for quantitative image-based 
cytometry (QIBC) was performed as described (Toledo et al., 2013). Images were 
acquired either with a 4x or 10x objective under non-saturating conditions. Color-
coded scatter plots of asynchronous HeLa and RPE1-hTERT cell populations were 
generated with Spotfire data visualization software (TIBCO). 
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Analysis of metaphase chromosomes 
Colcemid-treated metaphase cells were spread on microscope slides and 
chromosomes stained with 7% Giemsa. After washing with water and air-drying 
overnight, coverslips were mounted on the slides using DPX mounting medium 
(Merck Millipore) or Permount (Fisher Scientific). 
 
Protein immunoprecipitations 
Cells were washed in PBS and lysed in LAP buffer, as previously described (Matos et 
al., 2011). Cleared lysates were normalized for total protein content and incubated 
with GFP-Trap matrix (Chromotek) for 90 min at 4°C, followed by extensive washing 
with LAP buffer. 
 
Nuclease assays 
MUS81-FLAP and SLX4-FLAP were semi-purified using GFP-Trap beads. 
Immunoprecipitates were incubated with 5’-32P- or 5’-Cy3-end-labeled synthetic 
replication forks or Holliday junctions (Matos et al., 2011). Cleavage products were 
separated by native PAGE and analyzed by phosphorimaging or fluorescence 
scanning. Resolution activity (% of cleavage) was calculated as the fraction of nicked 
duplex DNA product relative to the sum of the intact substrate and resolution product. 
 
Statistical analysis 
The number of cells or chromosomes analyzed as well as the number of independent 
experiments performed is indicated in the figure legends. Error bars on all graphs are 
SEM or SD. PRISM 6 software (Graphpad) was used for statistical analyzes. 
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FIGURE LEGENDS: 
 
Figure 1. MUS81 is active during S-phase and targeted to under-replicated 
regions by SLX4 during mitosis. See also Figures S1 and S2. 
 
(A) HeLa cells expressing MUS81-FLAP were released from a double thymidine 
block. MUS81-FLAP immunoprecipitates (IPs) were analyzed by western blotting 
and for RF-processing activity. * indicates 5´-labeling. See Note 1 in Extended 
Experimental Procedures describing evidence for two isoforms of MUS81: MUS81 
and MUS81short. 
 
(B) Quantification of mitotic index and RF processing activity of MUS81-FLAP from 
(A). Substrate cleavage was normalized to MUS81 protein levels.  
 
(C) DNA content analysis of cells from (A) and (B) by FACS. 
 
(D) MUS81-FLAP was immunoprecipitated from control or SLX1-depleted HeLa 
cells synchronized with thymidine (Thy) or nocodazole (Noc). IPs were analyzed as 
in (A). 
 
(E) Immunofluorescence (IF) analysis of SLX4-FLAP, MUS81, TOPBP1 and -
H2AX in HeLa cells. Nucleoplasmic proteins were pre-extracted. 
 
(F) Distribution of SLX4-FLAP foci number in individual prometaphase cells from 
(E), quantified from three independent experiments (mean ± SD, n>90 cells). 
 
(G) IF analysis of MUS81 localization at prometaphase in cells treated with the 
indicated siRNAs. 
 
(H) Distribution of MUS81 foci in individual prometaphase cells from (G), quantified 
from three independent experiments (mean ± SD, n>90 cells/condition). 
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(I) Mean number of MUS81 foci per prometaphase cell and frequency of 
colocalization with TOPBP1 from (G) (± SEM), quantified from 3 (>90 prometaphase 
cells) and 2 (>50 TOPBP1-positive cells) independent experiments. 
 
Figure 2. WEE1 inhibition elicits CDK1 and PLK1-dependent recruitment of 
active MUS81-SLX4 nuclease to S-phase chromosomes. See also Figure S2. 
 
(A) Schematic representation of human SLX4 with the domains required for 
interaction with XPF (blue), MUS81 (brown) and SLX1 (orange). The approximate 
relative position of all minimal CDK1 consensus sites (S/TP) is depicted. Residues in 
red are phosphorylated in vivo (source: http://www.phosphosite.org). 
 
(B) HeLa cells were transfected with the indicated vectors to express FLAG-tagged 
SLX4WT or SLX441A and synchronized at prometaphase with nocodazole. Cell lysates 
and anti-FLAG immunoprecipitates were analyzed for the indicated proteins. 
 
(C) HeLa cells were transfected with the indicated vectors and treated and analyzed as 
in (B). SLX46A has Alanine substitutions at T1524, T1544, T1561, T1571, T1676 and 
S1681. SLX435A has Alanine substitutions in all S/TP sites not mutated in SLX46A.  
 
(D) HeLa cells expressing SLX4-FLAP were released from a double thymidine block 
in the presence of DMSO, MK-1775 (WEE1i), WEE1i + RO-3306 (CDK1i) or 
WEE1i + BI2536 (PLK1i). SLX4-FLAP IPs were analyzed for the indicated proteins 
and for RF-processing activity. * indicates 5´-labeling. 
 
(E) Quantification of the mitotic index and RF processing activity from (D). RF-
processing activity of MUS81-FLAP IPs from Figure S2D is plotted for comparison. 
Substrate cleavage was normalized to SLX4 or MUS81 protein levels. 
 
(F) Representative images of MUS81 and SLX4-FLAP localization 3 hr after release 
from single thymidine block and quantification of MUS81 localization (nucleolar vs. 
pan-nuclear foci). Pan-nuclear MUS81 foci were found in 7 ± 0.53% (control) and 95 
± 1.45% (WEE1i-treated) of all interphase cells (mean ± SEM; n> 200; 3 independent 
experiments). 
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(G) PCNA was stained and visualized as in (F). PCNA localization was quantified 
from two independent experiments (n>200 cells/condition). 
 
Figure 3. WEE1 restrains MUS81-SLX4 association during S-phase to prevent 
pulverization of replicating chromosomes. See also Figure S3. 
 
(A) HeLa cells expressing MUS81-FLAP were released from a double thymidine 
block in the presence or absence of WEE1i. DNA content was analyzed by FACS. A 
direct comparison of the DNA content of three samples at the indicated time points is 
shown (right panel). 
 
(B) Mitotic index (%) of cells synchronized as in (A). 
 
(C) Soluble extracts prepared from samples collected in (A) were analyzed by western 
blotting. 
 
(D) MUS81-FLAP IPs from extracts prepared as in (C) were analyzed by western 
blotting. 
 
(E) Representative images of metaphase spreads prepared from cells treated as in (A) 
10 hr after thymidine release. 
 
(F) Quantification of chromosomal morphologies in (E), n=169. The data corresponds 
to a single experiment but identical results were observed in 6 independent 
experiments. 
 
(G) HeLa cells were synchronized and treated as in (A). Samples were collected 5 hr 
after release and DNA analyzed by PFGE. 
 
(H) Asynchronous HeLa cells were treated with HU (2mM) and ATR inhibitor AZ-20 
(1μM) to induce replication catastrophe, or with WEE1i, pre-extracted, stained for -
H2AX and RPA, and analyzed by quantitative image-based cytometry. Color-code: 
Mean -H2AX levels. 
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(I) Bar chart depicting cell population averages of chromatin-bound RPA from (H). 
 
Figure 4. CDK1 and PLK1 promote MUS81-EME2-SLX4-dependent 
chromosome pulverization in the absence of WEE1 activity. See also Figure S4. 
 
(A) HeLa cells were released from a double thymidine block in the presence of 
DMSO or the indicated inhibitors. DNA content was analyzed by FACS. 
 
(B) Metaphase spreads of cells treated as in (A) were prepared 6 hr after release from 
thymidine block. For each condition, representative images and frequency of 
pulverized metaphases are shown. 
 
(C) Cells were treated as in (A). Samples were collected 5 hr after release and DNA 
was analyzed by PFGE. The ratio of broken to total DNA was quantified from three 
experiments (mean ± SEM). 
 
(D) Synchronized HeLa cells, siRNA-depleted for the indicated proteins, were 
collected and analysed by PFGE as in (C). 
 
(E) Metaphase spreads of cells treated as in (D) were prepared 6 or 8 hr after release 
from the second thymidine block. Representative images are shown. Frequency of 
pulverized metaphases was determined from three independent experiments (mean ± 
SD). “Non-pulverized” chromosomes were either intact or displayed moderate levels 
of DNA breakage. 
 
(F) Subconfluent HAP1 cells with the indicated genotypes were cultured in the 
absence or presence of WEE1i for 14 hr. Soluble extracts were analyzed for the 
indicated proteins. * indicates an unspecific signal. 
 
Figure 5. WEE1 suppresses MUS81-EME2-SLX4-dependent cell death. See also 
Movie S1. 
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(A) HeLa cells expressing H2B-mCherry, siRNA-depleted for the indicated proteins, 
were released from a double thymidine block in the presence of WEE1i. Time-lapse 
microscopy was used to follow cellular and chromatin morphologies. Metaphase plate 
formation was quantified in cells that had undergone mitotic cell rounding. 
Representative DIC and H2B-mCherry images are shown. >100 cells were analyzed 
for each condition. 
 
(B) Nuclear division was analyzed and quantified from reattaching cells in (A) (n>50 
per condition). Representative images are shown. 
 
(C) Survival of asynchronous HAP1 cells of the indicated genotypes after 22 hr 
WEE1i treatment was monitored by time-lapse microscopy. The surviving fraction 
was quantified from three experiments (mean ± SD, n>100 cells / condition). 
 
(D) HAP1 cells of the indicated genotypes were treated with DMSO or WEE1i for 6 
hr. Cell survival was monitored with a clonogenic assay. Data points representing the 
surviving fraction are plotted in a log10 scale and denote mean ± SEM, derived from 
three replicates (*p< 0.05, two tailed t-test). 
 
(E) Fanconi Anemia patient cells (FA-P) transduced with constructs expressing the 
indicated versions of SLX4 were treated with DMSO or WEE1i for 6 hr. Cell survival 
was monitored with a luciferase-based assay. Data points representing the surviving 
fraction are plotted in log10 scale and denote mean ± SEM, derived from three 
replicates (*p< 0.05, two tailed t-test). 
 
Figure 6. WEE1 inhibition during S-phase causes MUS81-EME2-SLX4-
dependent premature entry into mitosis. See also Figures S5, S6 and Movie S2. 
 
(A) HeLa Kyoto cells were released from a double thymidine block in the presence of 
the indicated kinase inhibitors. Mitotic cell rounding was monitored by time-lapse 
microscopy and represented as mitotic index over time. Mitotic entry was defined as 
first frame in which the cell had fully rounded up. 
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(B) Box-and-whiskers plots depict median time of mitotic entry of cells in (A); n>50, 
whiskers represent 95% confidence interval. Asterisks indicate significant differences 
(*p< 0.05, ****p< 0.0001; two-way ANOVA). 
 
(C) HeLa cells, transfected twice with siRNAs targeting transcripts of the indicated 
proteins, were released from a double thymidine block in the presence of WEE1i. 
Cells were analyzed as in (B) (n>50 cells). 
 
(D) HeLa FRT/TO cells conditionally expressing siRNA-resistant MUS81-WT-SF or 
MUS81-ND-SF were siRNA-depleted for the indicated proteins. 24 hrs after 
induction of MUS81 expression, cells were released from a double thymidine block in 
the presence of WEE1i. Cells were analyzed as in (B) (n>50 cells). 
 
(E) HeLa cells, siRNA-depleted for the indicated proteins, were released from a 
double thymidine block in the presence of WEE1i. Cells were analyzed as in (B) 
(n>50 cells). 
 
(F) Asynchronously proliferating HeLa cells were treated with siRNAs as indicated, 
exposed to WEE1i for 3hrs with a 20 minute EdU pulse at the end of the treatment, 
stained for γ-H2AX, Cyclin B1 and EdU, and analyzed by quantitative image-based 
cytometry. Scatter plots depict mean EdU intensities versus total nuclear DAPI 
intensities. Color-code: Mean Cyclin B levels. 
 
(G) Data from (F) plotted to depict mean nuclear Cyclin B levels vs. total nuclear 
DAPI intensities. Color-code: Mean γ-H2AX levels. 
 
(H) The bar chart depicts mean nuclear Cyclin B levels in cell cycle staged population 
averages according to their DAPI/EdU profiles in (S6C). 
 
(I) The bar chart depicts mean nuclear γ-H2AX levels in cell cycle staged population 
averages according to their DAPI/EdU profiles in (S6C). 
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Figure 7. WEE1- and ATR-independent suppression of CDK1 activity and 
mitotic entry during S-phase 
 
(A) HeLa cells, transfected with the indicated siRNAs, were released from a double 
thymidine block in the presence of WEE1i. DNA content was analyzed by FACS. 
 
(B) Protein extracts from cells collected in (A) were analyzed by western blotting. 
 
(C) HeLa cells, siRNA-depleted for EME2, were released from a double thymidine 
block in the presence of the indicated inhibitors and analyzed as in (A) and (B). 
 
(D) HeLa cells, siRNA-depleted for the indicated proteins, were released from a 
double thymidine block in the presence of the indicated kinase inhibitors (500 nM 
WEE1i; 2 μM ATRi (VE-821); 10 μM ATMi (KU-55933). Mitotic cell rounding was 
monitored by time-lapse microscopy. Box-and-whiskers plots depict median time of 
mitotic entry. Whiskers represent a 95% confidence interval, n>50 cells. Asterisks 
indicate significant differences (****p< 0.0001; two-way ANOVA). 
 
Figure 8. A mechanism for controlled breakage of under-replicated 
chromosomes during mitosis 
 
(A) WEE1 kinase inhibits CDK1 during S-phase, indirectly preventing MUS81-SLX4 
association. PLK1 promotes MUS81-SLX4 association but is not essential for 
complex assembly. During mitosis, multiple MUS81 molecules are bridged by SLX4, 
which can dimerize (Guervilly et al., 2015). However, it is unclear whether SLX4 
dimerization is cell cycle regulated or required for the bridging of MUS81 molecules. 
MUS81 represents MUS81-EME2 heterodimers. 
 
(B) Working model: a double-negative feedback loop ensures that DNA replication 
and mitosis are temporally separated. Ongoing DNA replication delays entry into 
mitosis. In turn, CDK1- and PLK1-dependent assembly of MUS81-SLX4 at the G2/M 
transition ensures nucleolytic processing of any residual replication intermediates (top 
panel). 
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In cells treated with WEE1 inhibitors, premature association of SLX4 and MUS81 
promotes chromosome pulverization (middle panel). After depletion of MUS81-
EME2 or SLX4, WEE1 inhibition no longer halts the bulk of DNA replication. M-
phase entry is concurrently delayed, suggesting that ongoing replication delays the 
onset of mitosis (bottom panel). 
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 SUPPLEMENTAL FIGURES 
 
 
 Figure S1. MUS81-associated HJ-processing activity is cell cycle regulated and prematurely 
enhanced after WEE1 inhibition (Related to Figure 1 and Figure 2) 
 
(A) HeLa cells expressing MUS81-FLAP were synchronized at G1/S with thymidine or at 
prometaphase with nocodazole. MUS81-FLAP was affinity purified from extracts and analyzed by 
western blotting for the indicated proteins. (B) Immunoprecipiates from (A) were split and incubated 
with a model RF substrate. Cleavage reactions were carried out for the indicated times. * indicates 5´-
labelling. (C) Quantification and graphical display of the RF-resolution activity from (B). Values were 
quantified from three independent MUS81-FLAP immunoprecipitations and resolution assays (mean ± 
SD). (D) HeLa cells expressing MUS81-FLAP, treated with no siRNAs, control siRNAs or siRNAs 
targeting SLX4, were synchronized at G1/S by a double thymidine block and released in the presence 
of DMSO or MK-1775 (WEE1i). MUS81-FLAP was affinity purified from the extracts and analyzed 
by western blotting for the presence of the indicated proteins and for HJ-processing activity. * indicates 
5´-labelling. Some of the western blots in the left panel are identical to the ones in Figure 1A. HJ 
resolution was assayed in the same time course samples. Quantification and graphical display of the 
HJ-resolution activity is shown. Substrate cleavage was normalized to MUS81 protein levels in the IPs. 
(E) Soluble extracts corresponding to Figure 1D. HeLa cells expressing MUS81-FLAP were treated 
with control siRNAs or siRNAs targeting SLX1, and synchronized with thymidine (Thy) or nocodazole 
(Noc) for 18 hours. Soluble extracts were analyzed for the indicated proteins by western blotting.  
 
  
  
 
Figure S2. MUS81 nuclease activity on model replication forks is independent of WEE1, CDK1 
and PLK1 kinases (Related to Figure 1 and Figure 2) 
 
(A) MUS81-FLAP was affinity-purified from HeLa cells synchronized with thymidine (Thy) or 
nocodazole (Noc). Soluble extracts, anti-FLAP and anti-SLX4 IPs were analyzed for the indicated 
proteins. (B) HeLa cells expressing MUS81-FLAP treated with control siRNAs or siRNAs targeting 
SLX4 were synchronized at prometaphase with nocodazole. Soluble extracts and anti-FLAP IPs were 
analyzed as in (A). (C) SLX4-FLAP was affinity-purified from control or MUS81-depleted HeLa cells, 
 and synchronized with thymidine (Thy) or nocodazole (Noc). IPs were analyzed by western blotting 
for the indicated proteins and for RF processing activity. * indicates 5´-labeling. (D) HeLa cells 
expressing MUS81-FLAP were synchronized at G1/S by a double thymidine block and released in the 
presence of DMSO, MK1775 (WEE1i), WEE1i + RO-3306 (CDK1i) or WEE1i + BI2536 (PLK1i). 
MUS81-FLAP was affinity purified from extracts and analyzed for RF processing activity. * indicates 
5´-labelling. Substrate cleavage was normalized to MUS81 protein levels. (E) Representative images of 
SLX4-FLAP and MUS81 localization in prometaphase cells treated as in Figure 2F. Control cells were 
fixed 9 hr after thymidine release. (F) Cells prepared as in (E) were stained for SLX4-FLAP, MUS81, 
TOPBP1 or γ-H2AX. The plotted values represent the mean number of foci per prometaphase cell (± 
SEM). > 90 cells, pooled from 3 experiments, were analyzed for each staining and for each condition. 
(G) WEE1 prevents widespread DNA damage during S-phase. HeLa cells were synchronized at G1/S 
by a single thymidine block and released in the absence or presence of MK-1775 (WEE1i). γ-H2AX 
was stained and analyzed 3 hours after release (S-phase chromosomes). Representative images are 
shown. 200 cells were analyzed for each condition and γ-H2AX distribution (pan-nuclear vs. no 
staining/foci) was quantified. 
 
  
  
 
Figure S3. Chromosome pulverization upon WEE1 inhibition is not caused by RPA exhaustion 
or apoptotic cell death (Related to Figure 3). 
 
(A) Metaphase spreads were prepared from asynchronously proliferating HeLa cells treated for 9 hours 
with DMSO or WEE1i (500 nM). Representative images of the observed chromosomal morphologies 
are shown. In a parallel experiment, DNA content was monitored by FACS at the indicated time points 
 after treatment with DMSO or WEE1i. (B) Asynchronously proliferating HeLa cells were treated for 
the indicated time periods with a combination of HU (2mM) and ATR inhibitor AZ-20 (1µM) to 
induce replication catastrophe, or with WEE1i (500nM), pre-extracted, stained for γ-H2AX and RPA, 
and analyzed by quantitative image-based cytometry. Color-code: Mean γ-H2AX levels. (C) 
Asynchronously proliferating HeLa cells, siRNA-depleted for the indicated protein, were treated with 
WEE1i (500nM) for 3 hours, pre-extracted, stained for γ-H2AX and analyzed by quantitative image-
based cytometry. Color-code: Mean γ-H2AX levels. (D) HeLa cells were synchronized at G1/S by a 
double thymidine block and released in the presence of WEE1i. Protein extracts were analyzed by 
western blotting for the indicated proteins. PARP cleavage and Caspase 3 cleavage are hallmarks of 
programmed cell death by apoptosis. As a positive control for the visualization of apoptotic markers, 
HAP1 cells were treated with WEE1i for 14 hours, which results in the death of a significant part of the 
population (> 80% after 24hr, Figure 5C). 
 
 
  
  
Figure S4. MUS81, EME2 and SLX4-dependent DNA damage after WEE1 inhibition (Related to 
Figure 4) 
 
(A) HeLa cells, siRNA-depleted for the indicated proteins, were synchronized using a double 
thymidine block. Samples were collected 5 hours after release and extracts analyzed by western 
blotting for the indicated proteins. * indicates an unspecific signal. Samples from the same cultures 
were analyzed by PFGE in Figure 4D. (B) HeLa FRT/TO cells conditionally expressing MUS81-WT-
SF or MUS81-ND-SF (Nuclease-Dead) were induced for 16 hours. MUS81-SF was affinity-purified 
 using FLAG-beads and IPs were analyzed for nuclease activity on a nicked HJ (nHJ) or a replication 
fork (RF) substrate. *indicates 5´-labeling. MUS81-ND contains the D307A mutation, which impairs 
its catalytic activity. The SF tag is composed of StrepII-FLAG. (C) HeLa FRT/TO cells conditionally 
expressing siRNA-resistant MUS81-WT-SF or MUS81-ND-SF (Nuclease-Dead) were siRNA-depleted 
for the indicated proteins. 24 hours after induction of MUS81 expression, cells were released from a 
double thymidine block in the presence or absence of WEE1i. Soluble extracts from samples collected 
8 hours after release from G1/S were analyzed by western blotting for the indicated proteins. KU70 
was used as a loading control. (D) Metaphase spreads were prepared from cells treated as in (C), 
collected 8 hours after release from the second thymidine block. The frequency of pulverized 
metaphases is shown (top graph)(mean ± SEM). >100 metaphases were analyzed for each condition in 
3 biological replicates. Examples of pulverized vs. intact chromosomes are shown (bottom panel). (E) 
Western blot analysis of protein extracts from asynchronous RPE1-hTERT cells transfected with 
siRNAs targeting the indicated proteins. DMSO or WEE1i was added to cultures 12 hours prior to 
sample collection. (F) Schematic representation of the consensus transcript for full-length MUS81 and 
a putative transcript encoding a version of MUS81 that lacks the initial 75 amino-acids, which we have 
named MUS81short. The consensus transcripts for EME1 and EME2 are also shown. (*) marks the 
approximate positions of frameshift-inducing mutations introduced in HAP1 cells, using CRISPR-
Cas9. 1bp insertion in exon 2 that results in the specific disruption of full length MUS81; 10bp deletion 
in exon 2 disrupts EME1; 1bp deletion in exon 3 disrupts EME2. (G) Subconfluent HAP1 cells with 
the indicated genotypes were cultured in the absence or presence of WEE1i for 12 hours. Samples were 
collected and DNA was analyzed by PFGE. Note: While DNA breakage upon WEE1 inhibition is 
strongly dependent on the integrity of MUS81, EME1 and EME2, in HAP1 cells, DNA appears to be 
further processed, potentially by additional enzymes. MUS81-mediated apoptotic cell death may 
trigger the additional DNA degradation. 
 
  
  
 
Figure S5. WEE1 inhibition causes premature entry into mitosis in pre-synchronized cells. 
(Related to Figure 6) 
 
(A) HeLa cells, siRNA-depleted for the indicated proteins, were released from a double thymidine 
block in the presence of WEE1i or DMSO. DNA content was analyzed by FACS. (B) HeLa cells, 
siRNA-depleted for the indicated proteins, were synchronized by a double thymidine block and 
released in the presence of WEE1i or DMSO. Time-lapse microscopy was used to follow mitotic cell 
rounding, with pictures taken at 10-minute intervals. Mitotic index over the course of 22 hours is 
depicted for cells treated with DMSO (left graph) or WEE1i (right graph). For comparison purposes the 
“DMSO siControl” data is also displayed in the right graph. Corresponding mitotic entry data is plotted 
in Figure 6E. 
 
  
  
 
Figure S6. WEE1 inhibition causes premature entry into mitosis in asynchronous cells. (Related 
to Figure 6) 
 
(A) Scatter plot of the QIBC data from Figure 6F, displaying mean Cyclin B intensities at different 
stages of S-phase. Box shows the median value. (B) QIBC data from Figure 6F. Scatter plots depict 
mean EdU intensities versus total nuclear DAPI intensities. Color-code: Mean γ-H2AX levels. (C) 
 QIBC data from Figure 6F. Scatter plots depict mean EdU intensities versus total nuclear DAPI 
intensities. Color code: G1, Blue ; early S, Green ; mid S, Red ; late S, Yellow; G2/M, Purple. (D) 
Representative images of the QIBC data from Figure 6F.  
 
 
  
  
 
Figure S7. WEE1 inhibition causes DNA damage and EME2-dependent premature entry into M-
phase in RPE1-hTERT cells (Related to Figure 7) 
 
(A) RPE1-hTERT cells, siRNA-depleted for the indicated proteins, were synchronized by a single 
thymidine block and released in the presence of WEE1i (2.5 µM) or DMSO. DNA content was 
analyzed by FACS; pictures taken at 1-hour intervals to monitor mitotic index; Western blot analysis of 
soluble extracts from samples collected at 2-hour intervals is shown for the indicated proteins. Note: 
The population of cells in G1 that were not synchronized by thymidine at t=0 hr (approx. 20%) was 
gated out at all time points in order to facilitate visualization of progression through S-phase. (B) 
 Asynchronously proliferating RPE1-hTert cells were treated with siRNAs as indicated and exposed to 
WEE1i (2.5 µM) for 3h, stained for γ-H2AX and analyzed by quantitative image-based cytometry. 
Scatter plots depict mean γ-H2AX levels in the whole population. (C) Asynchronously proliferating 
RPE1-hTERT cells were treated as in (B), stained for Cyclin B and DAPI, and analyzed by quantitative 
image-based cytometry. Scatter plots depict mean nuclear Cyclin B levels versus total nuclear DAPI 
intensities. Color-code: Mean Cyclin B levels. (D) The bar chart depicts mean nuclear Cyclin B levels 
from (C) in cell cycle staged population averages according to their DAPI profiles in (E and F). (E) 
Cell cycle staging and gating of cells analyzed in (C and D) by quantification of DNA content (DAPI) 
using QIBC. (F) The bar chart depicts total DAPI intensity per nucleus from cells in (C). 
 
 
 
 
  
 SUPPLEMENTAL MOVIE LEGENDS 
 
Movie S1. Time-lapse recording of HeLa cells expressing Histone 2B-mCherry treated with 
WEE1i (Related to Figure 5) 
 
(A) Cells were released from a double thymidine block and treated with DMSO. Pictures were taken 
every 10 minutes following release from the second thymidine block. Time post thymidine release is 
indicated. (B) Cells were released from a double thymidine block and treated with WEE1i (500 nM). 
Pictures were taken every 10 min following release from the second thymidine block. Time post 
thymidine release is indicated. (C) Cells transfected with siRNAs targeting EME2 were released from a 
double thymidine block and treated with WEE1i (500 nM). Pictures were taken every 10 min following 
release from the second thymidine block. Time post thymidine release is indicated. 
 
Movie S2. Time-lapse recording of control HeLa cells treated with WEE1i (Related to Figure 6) 
 
(A) Cells transfected with control siRNAs were released from a double thymidine block and treated 
with DMSO. Pictures were taken every 10 min following release from the second thymidine block. 
Time post thymidine release is indicated. (B) Cells transfected with control siRNAs were released from 
a double thymidine block and treated with WEE1i. Pictures were taken every 10 min following release 
from the second thymidine block. Time post thymidine release is indicated. (C) Cells transfected with 
siRNAs targeting EME2 were released from a double thymidine block and treated with WEE1i. 
Pictures were taken every 10 min following release from the second thymidine block. Time post 
thymidine release is indicated. 
 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Tissue culture and cell lines 
RPE1-hTERT, HAP1 (Carette et al., 2011), HeLa FRT/TO and HeLa Kyoto cells were maintained in 
Dulbecco’s Modified Eagle Media (DMEM), supplemented with 10% fetal bovine serum (FBS). FA-P 
cells were maintained in DMEM supplemented with 20% FBS. All cultures were grown at 37°C in a 
humidified atmosphere containing 5% or 10% CO2. 
HAP1 cells carrying CRISPR/Cas9-induced mutations in MUS81 (HAP1_MUS81_14843-02), EME1 
(HAP1_EME1_07401-04) and EME2 (HAP1_EME2_01949-12) were purchased from Haplogen 
Genomics. HAP1 cell lines were initially haploid (~1n) but quickly stabilized their DNA content at a 
diploid (~2n) level, as assayed by FACS. All experiments were performed with ~2n HAP1 cells. 
Stable HeLa FRT/TO cell lines modified with siRNA-resistant MUS81-WT-SF, MUS81-ND-SF 
(nuclease-dead, D307A), SLX4-WT-Venus-FLAG, SLX4-41A-Venus-FLAG, SLX4-35A-Venus-
FLAG or SLX4-6A-Venus-FLAG, were induced with 1 mg/mL doxycycline 20-24 hours prior to 
harvesting. SF: StrepII-FLAG tag (Gloeckner et al., 2009); pcDNA5/FRT/TO-Venus-Flag-Gateway 
(1124) was a gift from Jonathon Pines (Addgene plasmid # 40999). SLX4-41A was prepared by gene 
synthesis (GeneArt, Thermo Fisher Scientific). SLX4-35A and SLX4-6A were prepared by swapping a 
restriction fragment (BstBI, EcoRI) between SLX4-41A and SLX4-WT 
HeLa Kyoto cells stably expressing MUS81-FLAP (CLJM6) (Matos et al., 2011) or SLX4-FLAP 
(CLJM59) (this study) were generated using BAC recombineering (Poser et al., 2008).  
Note 1: While analyzing MUS81 levels in the HAP1 KO cell lines we made an unexpected 
observation. Introduction of a frameshift mutation in Exon 2 eliminated the full-length MUS81 protein, 
as predicted. However, it did not alter the levels of a faster migrating protein that cross-reacted with 
anti-MUS81 antibodies (MUS81short, ~50 kDa) (Figures 4F and S4F). In contrast, a frameshift mutation 
in Exon 3 led to elimination of both forms of MUS81 (data not shown). MUS81short is detected in a 
variety of additional cell lines, such as HeLa Kyoto, U2OS and RPE1-hTERT, and can be efficiently 
depleted by siRNAs targeting exon 14 of MUS81 (Figure S4A). Interestingly, a protein-coding splice 
variant of MUS81, that lacks Exon1 and most of Exon 2, has been predicted (Figure S4F). This variant 
would encode a version of MUS81 lacking the first 75 residues, which are required for association with 
SLX4 (Fekairi et al., 2009). Indeed, whereas MUS81short could be readily detected alongside 
 MUS81 in EME1 immunoprecipitates, SLX4 immunoprecipitates specifically lacked MUS81short 
(Figure 2D, S2A, S2C and data not shown). These observations raise the interesting possibility that in 
order to enable MUS81 to carry out SLX4-independent functions during mitosis, human cells evolved 
MUS81short, which is unable to associate with SLX4. 
Short-term and long-term cell survival assays 
HAP1 cells of the indicated genotypes were seeded into Lab-Tek II.8-Wells chambers (Milian SA). 
Cells were treated with DMSO or 500 nM MK-1775 and followed by time-lapse microscopy at 5-
minute intervals for 22 hours. Short term cell survival was calculated by determining the fraction of 
living cells to the total number of cells in the first (t = 2 h, set to 100% survival) and last (t = 22 h) 
frame of the movie and expressed as %. The shown numbers were averaged from 3 independent 
experiments. 
Long-term survival of HAP1 cells was determined using a clonogenic assay. In brief, HAP1 cell lines 
were plated at a density of 1000 cells per well in six-well plates and were allowed to adhere overnight. 
Cells were then treated with MK-1775 at final concentrations from 50 nM to 500 nM, or DMSO as a 
control. The drug was removed after 6 hours, followed by two washes with PBS, and cells were 
incubated in fresh medium. After one week, cells were fixed and stained with crystal violet solution 
(1% formaldehyde, 0.05 % crystal violet, 1% methanol). Plates were air-dried and the number of 
colonies on each plate was counted. 
Cell survival of FA-P cells was determined using a luciferase-based microtiter plate assay. In brief, 
FA-P cells were plated at a density of 1000 cells per well in opaque white 96-well plates (BD 
Biosciences, 353296) in triplicates and were allowed to adhere overnight. Cells were then treated with 
MK-1775 at final concentrations from 400 to 1200 nM, or DMSO as a control. The drug was removed 
after 6 hours, followed by two washes with PBS and cells were re-fed with growth medium (DMEM, 
supplemented with 20% FBS). Cell survival was determined five days later using the Cell Titer-Glo 2.0 
reagent (Promega) on a CLARIOStar microplate reader (BMG Labtech) according to the 
manufacturer's instructions. 
siRNA transfections and western blotting 
For siRNA-mediated protein depletion, cells were plated to ~30% confluency, 10-12 hr prior to 
transfection. In all experiments, cells were transfected using Lipofectamine RNAiMAX (Invitrogen). 
ON-TARGETplus siRNAs and siMax siRNAs were purchased from Dharmacon and Eurofins, 
respectively. The sequences (5ʹ to 3ʹ) are as follows:  
MUS81: CAGCCCUGGUGGAUCGAUAUU (Wechsler et al., 2011) 
EME2: GCGAGCCAGUGGCAAGAGA (Pepe and West, 2014) 
SLX1: UGGACAGACCUGCUGGAGAUU (Munoz et al., 2009) 
SLX4: (#1) AAACGUGAAUGAAGCAGAAUU; (#2) CGGCAUUUGAGUCUGCAGGUGUU; 
(Munoz et al., 2009; Wechsler et al., 2011) 
On-TARGETplus non-targeting pool (Dhamacon) #D-001810-10-20 
Non-specific control (Eurofins): UAAUGUAUUGGAACGCAUA 
Two rounds of siRNA transfection were used for MUS81 depletion, ~24 and ~48 hours before the 
experiment. 
The efficiency of protein depletion was monitored by western blotting 44-60 hr after transfection. 
Synchronization and mitotic time courses  
 To obtain cell cycle stage-specific synchronization, sub-confluent cells were treated for 18 hr with 
thymidine (2 mM) or for 15 hr with nocodazole (150 ng/ml). To follow the progression of G1/S 
arrested cells into mitosis, cells were synchronized with a double thymidine block (15-16 hours) and 
released into pre-warmed medium containing appropriate amounts of the following kinase inhibitors 
(or equivalent volumes of the appropriate solvents): WEE1 inhibition in HeLa Kyoto –400-500 nM 
MK-1775; 100-500 nM MK-1775 in HAP1 cells; 2.5 µM MK-1775 was used in RPE1-hTERT cells; 
400-1200 nM MK-1775 was used in FA-P cells. MK-1775 was purchased from Selleck Chemicals, 
batches S152501, S152503 and S152504. PLK1 inhibition - 200 nM BI2536 (Selleck Chemicals); 
CDK1 inhibition – 9 µM RO-3306 (Sigma). siRNA treatments were done 45-48 hours prior to release 
from the second thymidine block. 
The mitotic index was calculated by determining the fraction of rounded-up cells to the total number of 
cells and expressed as %. Images were acquired every hour using a Leica DM IL microscope with an 
Olympus C-7070 Wide Zoom camera. > 200 cells were inspected for each time point. 
Time-lapse microscopy 
HeLa Kyoto cells were seeded into Lab-Tek II.8-Wells chambers (Milian SA), siRNA-depleted for the 
indicated proteins, and synchronized by a double thymidine block (15-16 hours). Cells were released 
into pre-warmed Leibovitz’s L-15 medium without Phenol Red (Gibco) supplemented with 10% fetal 
bovine serum (FBS), which contained MK-1775 (WEE1i) or the corresponding amount of DMSO. The 
chambers were then transferred to a Zeiss 200M microscope outfitted with a Zeiss LifeCell station 
system controlled by Metamorph 7.7.11 software (Molecular Devices) or an Olympus IX 81 
microscope with an Olympus MM system controlled by Metamorph 7.7.7 software in an incubator box 
set to 37°C. Per condition, 3 positions were marked and imaged automatically every 10 min for 20-22 
hrs (starting 1.5 to 2 hours after release from the second thymidine block) using a 20x 0.8NA Plan 
Apochromat or a 20x 0.75NA UPlanSApo air objective and an ORCA-flash 4.0 V2 camera (Hamatsu). 
The progression of mitosis was followed by observing cell (DIC) and chromatin (H2B-mCherry 
fluorescence) morphology changes during the time course. Mitotic entry was defined as the first frame 
in which the cell had fully rounded up. Mitotic index was calculated as the fraction of rounded cells at 
a given time to the total number of rounded cells in the movie. Only living cells were counted. 
Metaphase plate formation and nuclear division were quantified in HeLa Kyoto cells stably expressing 
histone H2B-mCherry (Schmitz et al., 2010) (kindly provided by Daniel Gerlich, IMBA Vienna), and 
expressed as % of all rounded up cells or % of all rounded up cells that reattached during the video, 
respectively. Time-lapse images were acquired on an Olympus IX71 microscope outfitted with a 
DeltaVision Measure system controlled by Softworx 4.1.0 software (Applied Precision). Calculations 
and statistics were performed using Microsoft Excel and Graph Pad Prism. 
Immunofluorescence Microscopy 
HeLa Kyoto cells were grown on glass coverslips (ThermoScientific) added to the culture dishes, 
treated as indicated and then permeabilized with 0.3% Triton-X100 for 10 min on ice, followed by 20 
min fixation with 4% paraformaldehyde on ice and 1 min incubation with ice cold methanol. Cells 
were blocked for 1 h in 3% BSA + 0.05 % Tween 20 and incubated overnight with primary antibodies 
in BSA-Tween. The primary antibodies used were: rabbit anti-TOPBP1 (1:2000 or 1:1000, Abcam), 
mouse anti-MUS81 (1:1000, MTA30 2G10), rabbit anti-GFP (1:5000), mouse anti-GFP (1:1000, 
Roche), mouse anti-γ-H2AX (1:5000, Abcam). Secondary antibodies conjugated to Alexa555 (1:1000, 
Chemicon) and Alexa488 (1:1000, Chemicon) were used for detection. DNA was stained with DAPI 
and coverslips were mounted on microscope slides (Thermo Scientific) using ProLong® Gold Antifade 
Reagent (Life Technologies). 
Images were acquired using a Leica DM 6000B microscope using a HCX PL Fluotar x63, oil objective 
lens, and captured using an ORCA C4742-95-12ER camera (Hamamatsu) controlled by Openlab 5.0.2 
software (Improvision). Images were processed using Adobe Photoshop CS6 extended. 
Mean foci number was calculated by averaging the number of fluorescent foci in 2-3 independent 
experiments. Colocalization (expressed in %) was calculated by determining the fraction of foci that 
displayed co-staining to the total number of detected foci. ≥ 30 cells were inspected per condition and 
experiment. Calculations and statistics were performed using Graph Pad Prism or Microsoft Excel. 
Quantitative Image-Based Cytometry (QIBC) 
 Automated multichannel wide-field microscopy for quantitative image-based cytometry (QIBC, 
Figures 3H and I, 6F-I, S3B and C, S6A-D and S7B-F) was performed as described (Altmeyer et al., 
2013; Toledo et al., 2013) on an Olympus ScanR Screening System equipped with an inverted 
motorized Olympus IX83 microscope, a motorized stage, IR-laser hardware autofocus, a fast emission 
filter wheel with single band emission filters, and a 12bit digital monochrome CMOS camera with 
sensor chip FL-400 (2048 x 2048 pixels of size 6.5 x 6.5 µm). Images were acquired either with a 4x 
(NA 0.16) or 10x (NA 0.4) objective under non-saturating conditions. All images were analyzed by the 
inbuilt Olympus ScanR Image Analysis Software Version 2.5.1, a dynamic background correction was 
applied, and nuclei segmentation was performed using an integrated intensity-based object detection 
module. Pulsed 5-ethynyl-2'-desoxyuridine (EdU, Thermo Fisher) incorporation, total DAPI, mean 
intensities of Cyclin B (BD Transduction Laboratories C23420, 1:500), chromatin-bound RPA70 
(Abcam ab79398, 1:500) and γH2AX (Biolegend 613401, 1:1000; Cell Signaling 9718, 1:500) were 
analysed. Color-coded scatter plots of asynchronous HeLa and RPE1-hTERT cell populations were 
generated with Spotfire data visualization software (TIBCO). 
Analysis of metaphase chromosomes  
Cells were treated with 0.2 µg/ml colcemid 40-60 min prior to collection by mitotic shake-off, washed 
in PBS and swollen in 5 ml of 75 mM KCl for 15-30 min at 37°C. Ice-cold methanol/acetic acid (3:1 
ml) was added on top of the swelling buffer and the cells were centrifuged for 5 min at 800 rpm at RT. 
The two-layered solution was removed and the cells were fixed in 5 ml of ice-cold methanol/acetic acid 
(15 min on ice). Metaphase cells were then spread on microscope slides (Thermo Scientific) and 
washed with 2ml ice-cold methanol/acetic acid. After O/N air drying, surface spreads were stained with 
7% Giemsa for 7-10 minutes.  
 After washing with 50 ml water and air-drying overnight, coverslips were mounted on the slides using 
DPX mounting medium (Merck Millipore) or Permount (Fisher Scientific). 
Images were acquired using a Leica DM 6000B microscope using a HCX PL Fluotar x63, oil objective 
lens, and captured using an ORCA C4742-95-12ER camera (Hamamatsu) controlled by Openlab 5.0.2 
software (Improvision) or using an Olympus BX50 microscope using an UPlanApo 100x oil objective 
lens, and captured using an Sensicam XVGA (PCO) camera controlled by Live Acquisition 2.5.0.26 
software (FEI Life Sciences). 
Pulsed-field gel electrophoresis 
PFGE was performed as previously described (Hanada et al., 2007; Pepe and West, 2014). Briefly, 
5x105 Hela Kyoto cells were used to make low melting point agarose plugs using CHEF Mapper® XA 
system plug molds (Bio-Rad). Cells were centrifuged, resuspended in 50 µl of washing buffer (10 mM 
Tris-HCl pH 8.0, 100 mM EDTA) and mixed with 50 µl 1% (w/v) low melting point agarose in water. 
After polymerization at 4°C, plugs were incubated with lysis buffer (10 mM Tris-HCl pH 8.0, 100 mM 
EDTA, 1% (w/v) sodium lauryl sarcosine, 0.2% (w/v) sodium deoxycholate and 1 mg/ml proteinase K) 
at 37°C for 48 hours. Plugs were washed 2x in washing buffer and incubated overnight with RNase (10 
mM Tris-HCl pH 8.0, 10 mM EDTA, 1 mg/ml RNase A). Plugs were then washed in 10 mM Tris-HCl 
pH 8.0 and 100 mM EDTA, and loaded onto a 1% (w/v) agarose gel in 0.5% (v/v) TBE.  Gels were run 
for 23 hr at 13°C in a Gene Navigator PFGE apparatus (Amersham Biosciences) using the following 
parameters: voltage 180–120 V log; angle from 1201 to 1101 linear; interval 30 s to 5 s log. Gels were 
stained with 1.25 µg/ml ethidium bromide in 0.5% (v/v) TBE for 1 hr, washed in TBE and visualized 
using a GelDoc XR+ imager (Bio-Rad). Band quantifications were performed using ImageLab 
software. 
FACS analysis of DNA content 
Hela Kyoto cells were treated with trypsin, washed with PBS and fixed in ice-cold 70% ethanol 
overnight at 4°C. Prior to cytometric analysis, cells were washed with PBS and incubated with 50 µL 
of 100 µg/mL RNase A (Qiagen) and 200 µL of 50 µg/mL propidium iodide (Sigma).  
Cellular DNA content was determined using a FACSCalibur flow cytometer (BD Biosciences) and 
FACS data were analyzed using FlowJo 10.1 software. 
 Protein extraction, immunoprecipitations and western blotting 
Cells were washed in PBS, lysed in 500 µL LAP buffer, as previously described (Matos et al., 2011),  
and insoluble material was removed by centrifugation. Cleared lysates were normalized for total 
protein content (2-5 mg) and incubated with 15 µL of GFP-Trap matrix (Chromotek) for 90 min at 4°C 
(rotating wheel), followed by extensive washing with LAP buffer. 
Whole-cell lysates or immunoprecipitates were subjected to NuPAGE gel electrophoresis (NuPAGE 3-
8% Tris-Acetate; NuPAGE 7% Tris-Acetate or NuPAGE BOLT 4-12% Bis-Tris, Invitrogen) and 
blotted on PVDF membranes (GE Healthcare). Proteins were detected using mouse anti-MUS81 (Santa 
Cruz MTA30 2G10), mouse anti-GFP (Roche), mouse anti-EME1 (Santa Cruz MTA31 7H2), mouse 
anti-PLK1 (Santa Cruz sc-17783), mouse anti-γ-H2AX (1:5000, Abcam), rabbit anti-SLX4 (APE11, 
(Wyatt et al., 2013)), rabbit anti-SLX4 (A302-270A, Bethyl), rabbit anti-EME2 (APE13 (Pepe and 
West, 2014)), rabbit anti-cyclin E (Santa Cruz), Rabbit anti-H3-P (Abcam), rabbit anti-γ-H2AX 
(Abcam), rabbit anti-KAP1 (Abcam), apoptosis-detection cocktail (Abcam ab136812), rabbit anti-
CYK4-P-S157 (a gift from Mark Petronczki and Tohru Takaki), mouse anti-Cyclin B (BD), rabbit anti-
Cdc2-Y15-P (Cell Signaling Technology), mouse anti-CDC27 (BD), mouse-anti CHK1 (Santa Cruz 
sc-8408), rabbit-anti CHK1-S345-P (Cell Signaling), rabbit-anti RPA32 (A300-244 
A, Bethyl Laboratories), rabbit-anti RPA32-S33-P (A300-246A, Bethyl Laboratories). 
Nuclease assays 
For nuclease assays, MUS81-FLAP and SLX4-FLAP were immuno-affinity purified using GFP-Trap 
(Chromotek) beads and washed extensively. The beads (approx. volume 10 µl) were then mixed with 
10 µl cleavage buffer (50 mM Tris-HCl pH 7.5, 3 mM MgCl2, 10 ng/µl poly[dI-dC]) and 
approximately 1 nM 5’-32P-end-labeled synthetic Holliday junction (X26), 1 nM 5’-32P-end-labeled 
synthetic replication fork, or 15 ng  5’-Cy3-end-labeled synthetic replication fork (Ip et al., 2008). After 
incubation at 37°C with gentle rotation (10-15 min for RFs; 45 min for HJs), reactions were stopped by 
addition of 3 µl of 10 mg/ml proteinase K and 2% SDS, followed by incubation for 45 min at 37°C. 
Loading dye (4 µl) was then added and the labeled products were separated by 10% native PAGE and 
analyzed by phosphorimaging or fluorescence scanning using a Typhoon scanner. Band intensities 
were determined using ImageQuant software (GE Healthcare). Resolution activity (% of cleavage) was 
calculated by determining the fraction of nicked duplex DNA product relative to the sum of the intact 
substrate and resolution product. 
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